Biotechnology News and Research

RSS

Scientists offer first genetic proof of new and rational treatment for osteoporosis

The so-called RANK protein and the molecule that binds to it, the RANK ligand or RANKL, form a focus of the work of Josef Penninger, director of the Institute of Molecular Biotechnology (IMBA) in Vienna. In 1999 his group deleted the RANKL gene from mice and showed that the RANK/RANKL system was the "master regulator" governing bone loss (Kong et al. 1999 Nature 402, 304-309).

26 Nov 2009

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus.

25 Nov 2009

Simulations Plus launches new version of GastroPlus

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announces the release of GastroPlus Version 6.1, the latest version of its state-of-the-art software used by pharmaceutical research scientists for simulation of oral absorption, intravenous dosing, pharmacokinetics, and pharmacodynamics.

25 Nov 2009

iThemba Pharmaceuticals and Pyxis Discovery sign a collaborative agreement

iThemba Pharmaceuticals' service division and Pyxis Discovery announced today that they have signed a collaborative agreement to jointly market both companies' services.

25 Nov 2009

Illumina's Board of Directors authorize a new stock repurchase program

Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.

From Illumina, Inc. 25 Nov 2009

Vicor Technologies announces implementation of ASP distribution model in cardiology practice

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced the beta test installation of the company's application service provider (ASP) distribution model in a U.S. cardiology practice.

25 Nov 2009

Tennessee Biotechnology Association to host workshop on biotechnology industry

The Tennessee Biotechnology Association and its Graduate Alliance are jointly hosting an afternoon of biotech, business, and law on December 7th, 2009. This event will be held at Belmont University with a reception at 5pm sponsored by i3 Research.

25 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Pharmaceutical research and biotechnology companies test medicines and vaccines to treat HIV/AIDS

America's pharmaceutical research and biotechnology companies are testing 97 medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

25 Nov 2009

Ocimum Biosolutions' Biotracker awarded caBIG Bronze Compatibility Certification

Ocimum Biosolutions today announced that its specialty life science Laboratory Information Management System (LIMS), Biotracker™ has been awarded the prestigious caBIG® (cancer Biomedical Informatics Grid®) Bronze Compatibility Certification by the National Cancer Institute, an institute of the National Institutes of Health, U.S. Department of Health and Human Services.

24 Nov 2009

OmniComm Systems chosen as Beardsworth's preferred EDC provider

OmniComm Systems, Inc., one of the fastest growing companies in the EDC marketplace, today announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm's TrialMaster EDC solution for conducting a Phase II vaccine study.

24 Nov 2009

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical Inc. is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis.

24 Nov 2009

Hamilton Thorne announces financial results for third-quarter 2009

Hamilton Thorne Ltd., formerly Calotto Capital Inc., a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, today reported operational and financial results for the third quarter ended September 30, 2009

24 Nov 2009

Bayer CropScience, GVK Biosciences sign agreement to speed up innovative crop protection products

Bayer CropScience and GVK Biosciences Private Limited (GVK BIO), Hyderabad, India, have entered into a research cooperation in the area of early discovery chemistry. The objective is to speed up the search for promising active ingredients for innovative crop protection products.

24 Nov 2009

IFR scientists crystallise protein that may aid gut bacteria bind to the gastrointestinal tract

Scientists have crystallised a protein that may help gut bacteria bind to the gastrointestinal tract. The protein could be used by probiotic producers to identify strains that are likely to be of real benefit to people.

24 Nov 2009

SANYO releases whitepaper on its new cell culture CO2 incubator

SANYO North America's Biomedical and Environmental Division has released a new whitepaper showing that higher up-time ratios, based on new protocols that minimize incubator downtime when compared to conventional decontamination methods, can accelerate a return on investment in cell culture CO2 incubators that use hydrogen peroxide vapor (H2O2) in conjunction with narrow-bandwidth ultraviolet light and copper-enriched stainless steel.

24 Nov 2009

Andor Technology reports 2009 preliminary results

ANDOR TECHNOLOGY PLC ("Andor") Preliminary Results for the year ended 30 September 2009 24 November 2009 Andor Technology plc (AND.L), the leading developer and manufacturer of high performance digital cameras and solutions for academic, industrial and government applications globally, today announces preliminary results for the year ended 30 September 2009.

24 Nov 2009

Seattle Genetics and Agensys expand ADC collaboration

Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companies’ antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.

24 Nov 2009

Jubilant Organosys, UAB and Southern Research Institute announce joint venture to accelerate global drug development

Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S.-India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide.

24 Nov 2009

Proteon Therapeutics commences PRT-201 Phase 1/2 clinical study in hemodialysis patients

Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.

23 Nov 2009

Biotechnology News and Research

Scientists offer first genetic proof of new and rational treatment for osteoporosis

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Simulations Plus launches new version of GastroPlus

iThemba Pharmaceuticals and Pyxis Discovery sign a collaborative agreement

Illumina's Board of Directors authorize a new stock repurchase program

Vicor Technologies announces implementation of ASP distribution model in cardiology practice

Tennessee Biotechnology Association to host workshop on biotechnology industry

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Pharmaceutical research and biotechnology companies test medicines and vaccines to treat HIV/AIDS

Ocimum Biosolutions' Biotracker awarded caBIG Bronze Compatibility Certification

OmniComm Systems chosen as Beardsworth's preferred EDC provider

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Hamilton Thorne announces financial results for third-quarter 2009

Bayer CropScience, GVK Biosciences sign agreement to speed up innovative crop protection products

IFR scientists crystallise protein that may aid gut bacteria bind to the gastrointestinal tract

SANYO releases whitepaper on its new cell culture CO2 incubator

Andor Technology reports 2009 preliminary results

Seattle Genetics and Agensys expand ADC collaboration

Jubilant Organosys, UAB and Southern Research Institute announce joint venture to accelerate global drug development

Proteon Therapeutics commences PRT-201 Phase 1/2 clinical study in hemodialysis patients

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News